, Volume 201, Issue 1, pp 43–53

Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats

  • Morgane Thomsen
  • Anders Fink-Jensen
  • David P. D. Woldbye
  • Gitta Wörtwein
  • Thomas N. Sager
  • Rene Holm
  • Lauren M. Pepe
  • S. Barak Caine
Original Investigation



Dopamine D2-like partial agonists such as aripiprazole have received some attention as potential pharmacotherapies for the treatment of psychostimulant addiction. However, the preclinical evaluations so far have focused on acute effects of aripiprazole.


We tested the hypothesis that aripiprazole, both as acute and as chronic treatment, would preferentially decrease cocaine self-administration while sparing behavior maintained by a natural reinforcer, resulting in a shift in the allocation of behavior from cocaine-taking towards the alternative reinforcer.

Materials and methods

Rats were trained to self-administer intravenous cocaine in a concurrent choice procedure, with a palatable food as the competing reinforcer, under a fixed ratio (FR) 1 FR 5 chain schedule. Aripiprazole was then administered as continuous infusion by osmotic minipumps for 5 days, during which performance in the choice procedure was assessed daily.


An intermediate dose of aripiprazole decreased cocaine self-administration and shifted the cocaine choice curve to the right as an acute treatment. However, as a chronic treatment, aripiprazole failed to decrease cocaine self-administration or cocaine choice, despite a dose-dependent decrease in overall response rates and food-maintained behavior.


Our results confirm and extend earlier findings and indicate that acute administration of aripiprazole can decrease cocaine self-administration. However, based on the present data, chronic treatment with aripiprazole does not show much promise as a potential pharmacotherapy for cocaine addiction. Both acute and chronic treatment data are in agreement with published clinical findings, suggesting that the concurrent choice procedure in rats has predictive validity of efficacy in humans.


Self-administration Cocaine Concurrent choice schedule Chronic treatment Partial agonist 


  1. Bannon MJ (2005) The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol 204:355–360PubMedCrossRefGoogle Scholar
  2. Barone P, Tucci I, Parashos SA, Chase TN (1988) Supersensitivity to a D-1 dopamine receptor agonist and subsensitivity to a D-2 receptor agonist following chronic D-1 receptor blockade. Eur J Pharmacol 149:225–232PubMedCrossRefGoogle Scholar
  3. Barrett AC, Miller JR, Dohrmann JM, Caine SB (2004) Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47(Suppl 1):256–273PubMedCrossRefGoogle Scholar
  4. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF (2005) Aripiprazole in schizophrenia with cocaine dependence; a pilot study. J Clin Psychopharmacol 25:363–366PubMedCrossRefGoogle Scholar
  5. Bergman J, Kamien JB, Spealman RD (1990) Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav Pharmacol 1:355–363PubMedGoogle Scholar
  6. Braun AR, Laruelle M, Mouradian MM (1997) Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J Neural Transm 104:341–362PubMedCrossRefGoogle Scholar
  7. Brown ES, Jeffres J, Liggin JD, Garza M, Beard L (2005) Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotics to aripiprazole. J Clin Psychiatry 66:756–760PubMedCrossRefGoogle Scholar
  8. Caine SB, Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260:1814–1816PubMedCrossRefGoogle Scholar
  9. Caine SB, Koob GF (1995) Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose–effect function to the left under different schedules in the rat. Behav Pharmacol 6:333–347PubMedCrossRefGoogle Scholar
  10. Caine SB, Negus SS, Mello NK, Bergman J (1999) Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J Pharmacol Exp Ther 291:353–360PubMedGoogle Scholar
  11. Caine SB, Negus SS, Mello NK (2000) Effects of dopamine D1-like and D2-like agonists on cocaine self-administration in rhesus monkeys: rapid assessment of cocaine dose–effect functions. Psychopharmacology 148:41–51PubMedCrossRefGoogle Scholar
  12. Collins GT, Woods JH (2007) Drug and reinforcement history as determinants of the response-rate maintaining effects of quinpirole in the rat. J Pharmacol Exp Ther 323:599–605PubMedCrossRefGoogle Scholar
  13. Creese I, Chen A (1985) Selective D-1 dopamine receptor increase following chronic treatment with SCH 23390. Eur J Pharmacol 109:127–8PubMedCrossRefGoogle Scholar
  14. Do Carmo GP, Mello NK, Rice KC, Folk JE, Negus SS (2006) Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol 547:92–100PubMedCrossRefGoogle Scholar
  15. Emmett-Oglesby M, Mathis D (1988) Chronic administration of SCH 23390 produces sensitization to the discriminative stimulus properties of cocaine. In: Harris LS (ed) Problems of drug dependence. Proc 50th Annual Scientific Meeting, The College on Problems of Drug Dependence. United States Department of Health and Human Services, Rockville, p 367Google Scholar
  16. Grabowski J, Shearer J, Merrill J, Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439–64PubMedCrossRefGoogle Scholar
  17. Grech DM, Spealman RD, Bergman J (1996) Self-administration of D1 receptor agonists by squirrel monkeys. Psychopharmacology (Berl) 125:97–104CrossRefGoogle Scholar
  18. Gui-Hua C, Perry BD, Woolverton WL (1992) Effects of chronic SCH 23390 or acute EEDQ on the discriminative stimulus effects of SKF 38393. Pharmacol Biochem Behav 41:321–327CrossRefGoogle Scholar
  19. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology (Berl) 155:330–337CrossRefGoogle Scholar
  20. Haney M, Hart CL, Reed SC, Vosburg SK, Foltin RW (2007) Aripiprazole increases cocaine self-administration in humans. Oral presentation at International Study Group Investigating Drugs as Reinforcers (ISGIDAR), June 2007, Québec City, CanadaGoogle Scholar
  21. Hess EJ, Albers LJ, Le H, Creese I (1986) Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238:846–854PubMedGoogle Scholar
  22. Howell LL, Byrd LD (1992) Enhanced sensitivity to the behavioral effects of cocaine after chronic administration of D2-selective dopamine antagonists in the squirrel monkey. J Pharmacol Exp Ther 262:907–915PubMedGoogle Scholar
  23. Kleven MS, Woolverton WL (1990) Effects of continuous infusions of SCH 23390 on cocaine- or food-maintained behavior in rhesus monkeys. Behav Pharmacol 1:365–373PubMedGoogle Scholar
  24. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329–336PubMedGoogle Scholar
  25. Kosten TA (1997) Enhanced neurobehavioral effects of cocaine with chronic neuroleptic exposure in rats. Schizophr Bull 23:203–213PubMedGoogle Scholar
  26. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612–627PubMedCrossRefGoogle Scholar
  27. LeDuc PA, Mittleman G (1993) Interactions between chronic haloperidol treatment and cocaine in rats: an animal model of intermittent cocaine use in neuroleptic treated populations. Psychopharmacology (Berl) 110:427–436CrossRefGoogle Scholar
  28. Lile JA, Stoops WW, Vansickel AR, Glaser PEA, Lon R Hays LR, Rush CR (2005) Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of d-amphetamine in humans. Neuropsychopharmacology 30:2103–2114PubMedCrossRefGoogle Scholar
  29. McGavin JK, Goa KL (2002) Aripiprazole. CNS Drugs 16:779–786 discussion 787–8PubMedCrossRefGoogle Scholar
  30. Mello NK, Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14(6):375–424PubMedCrossRefGoogle Scholar
  31. Nader MA, Mach RH (1996) Self-administration of the dopamine D3 agonist 7-OH-DPAT in rhesus monkeys is modified by prior cocaine exposure. Psychopharmacology (Berl) 125:13–22CrossRefGoogle Scholar
  32. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T (2003) Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472:89–97PubMedCrossRefGoogle Scholar
  33. Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28:919–931PubMedGoogle Scholar
  34. Negus SS, Mello NK, Lamas X, Mendelson JH (1996) Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 278:879–890PubMedGoogle Scholar
  35. Pulvirenti L, Koob GF (2002) Being partial to psychostimulant addiction therapy. Trends Pharmacol Sci 23(4):151–153PubMedCrossRefGoogle Scholar
  36. Ranaldi R, Wang Z, Woolverton WL (2001) Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend 64:209–217PubMedCrossRefGoogle Scholar
  37. Riddle EL, Fleckenstein AE, Hanson GL (2005) Role of monoamine transporters in mediating psychostimulant effects. APPS Journal 7:E847–E851Google Scholar
  38. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223PubMedCrossRefGoogle Scholar
  39. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O’Brien CP, Sellers EM (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 56:1101–1106PubMedCrossRefGoogle Scholar
  40. Semba J, Watanabe A, Kito S, Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785–791PubMedCrossRefGoogle Scholar
  41. Shimokawa Y, Akiyama H, Kashiyama E, Koga T, Miyamoto G (2005) High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 821:8–14PubMedCrossRefGoogle Scholar
  42. Sinnott RS, Mach RH, Nader MA (1999) Dopamine D2/D3 receptors modulate cocaine’s reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend 54:97–110PubMedCrossRefGoogle Scholar
  43. Sofuoglu M, Kosten TR (2005) Novel approaches to the treatment of cocaine addiction. CNS Drugs 19:13–25PubMedCrossRefGoogle Scholar
  44. Sørensen G, Sager TN, Petersen JH, Brennum LT, Thøgersen P, Hee-Bengtsen C, Thomsen M, Wörtwein G, Fink-Jensen A, Woldbye DPD (2008) Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology 199:37–46PubMedCrossRefGoogle Scholar
  45. Stoops WW, Lile JA, Glaser PEA, Rush CR (2006) A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend 84:206–209PubMedCrossRefGoogle Scholar
  46. Stoops WW, Lile JA, Lofwall MR, Rush CR (2007) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am J Drug Alcohol Abuse 33(6):769–776PubMedCrossRefGoogle Scholar
  47. Thomsen M, Caine SB (2005) Chronic intravenous drug self-administration in rodents. Current Protocols in Neuroscience Unit 9.20. Wiley, New YorkGoogle Scholar
  48. Thomsen M, Caine SB (2007) Intravenous drug self-administration in mice: practical considerations. Behav Genet 37:101–118PubMedCrossRefGoogle Scholar
  49. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, Meririnne E (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 164(1):160–162PubMedCrossRefGoogle Scholar
  50. Vaccheri A, Dall’Olio R, Gandolfi O, Roncada P, Montanaro N (1987) Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390. Psychopharmacology (Berl) 91:394–396CrossRefGoogle Scholar
  51. Wee S, Wang Z, Woolverton WL, Pulvirenti L, Koob GF (2007) Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration. Neuropsychopharmacology 32:2238–2247PubMedCrossRefGoogle Scholar
  52. Wise RA, Murray A, Bozarth MA (1990) Bromocriptine self-administration and bromocriptine reinstatement of cocaine-trained and heroin-trained lever pressing in rats. Psychopharmacology 100:355–360PubMedCrossRefGoogle Scholar
  53. White FJ, Joshi A, Koeltzow TE, Hu XT (1998) Dopamine receptor antagonists fail to prevent induction of cocaine sensitization. Neuropsychopharmacology 18:26–40PubMedCrossRefGoogle Scholar
  54. Woolverton WL, Goldberg LI, Ginos J (1984) Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 230:678–683PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Morgane Thomsen
    • 1
  • Anders Fink-Jensen
    • 2
    • 3
  • David P. D. Woldbye
    • 2
    • 3
  • Gitta Wörtwein
    • 2
    • 3
  • Thomas N. Sager
    • 4
  • Rene Holm
    • 5
  • Lauren M. Pepe
    • 1
  • S. Barak Caine
    • 1
  1. 1.Alcohol and Drug Abuse Research CenterMcLean Hospital/Harvard Medical SchoolBelmontUSA
  2. 2.Laboratory of NeuropsychiatryRigshospitalet University HospitalCopenhagenDenmark
  3. 3.Department of Neuroscience and PharmacologyUniversity of CopenhagenCopenhagenDenmark
  4. 4.Division of NeurobiologyH. Lundbeck A/SValbyDenmark
  5. 5.Preformulation, H. Lundbeck A/SValbyDenmark

Personalised recommendations